The analysis of splicing patterns in the primary HIV-1 subtype B isolate P2149-3 has revealed unprecedented complexity in RNA processing, highlighting previously unrecognized mechanisms that may shape viral gene expression and pathogenesis. Through RT-PCR followed by nested amplification and automated size quantification using fluorescently labeled primers, we identified a series of doubly spliced (DS) transcripts with sizes inconsistent with known splice site usage in HIV-1. These anomalies were traced to the activation of two novel 3′ splice sites—A4d and A4h—for Rev RNA generation, as well as the emergence of atypical Nef transcripts.
A4d, located five nucleotides upstream of the canonical A4a site, was found to be the dominant splice site in P2149-3, utilized in over 60% of Rev transcripts across all time points post-infection. This site had only been previously reported in a T cell line-adapted virus (SF2) and a group O isolate (ANT70C), suggesting it is not a common feature of standard HIV-1 replication. The exon composition of A4d-containing transcripts was predominantly 1.4d.7 and 1.3.4d.7, indicating functional coding potential for Rev protein variants. Similarly, A4h, situated 20 nucleotides upstream of A4c, was detected in three distinct Rev isoforms: 1.4h.7, 1.2.4h.7, and 1.3.4h.7. Although less frequently used than A4d, its presence confirms the existence of an additional regulatory layer in Rev mRNA maturation.4,5-Difluorophthalic acid Biological Activity
Beyond Rev, the study uncovered three unusual Nef transcripts. One utilized the 3′ splice site A5a, located just 4 nt downstream of the usual A5 site, and another employed A7a—previously observed only in minor fractions within HXB2. Most striking was the identification of a transcript with exon structure 1.3.7, which involves splicing from D1 to A7, a pattern previously documented only in rare instances through deep sequencing of p89.6 isolates. These findings suggest that alternative splicing in primary HIV-1 isolates can generate a broader repertoire of protein isoforms than previously recognized.
Sequence analysis revealed key genomic features enabling this atypical splicing. For A4d, a strong polypyrimidine tract with nine pyrimidines interspersed with two purines and a branch point sequence identical to NL4-3’s supported efficient recognition. For A4h, although the polypyrimidine tract was suboptimal due to interruptions by purines, the presence of a conserved mammalian branch point consensus (UACAAAU) with five potential base pairings to U2 snRNP likely enhances splicing efficiency. Additionally, the sequence context around A4h in P2149-3 (AAG/G) aligns more closely with the optimal YAG/G consensus than the AAG/U sequences found in other subtype B strains, potentially increasing its competitive advantage.
These results challenge the conventional view of HIV-1 splicing as a highly constrained process governed by a limited set of canonical splice sites.Monomethyl In Vitro Instead, they demonstrate that primary isolates exhibit significant flexibility in splice site selection, possibly driven by subtle differences in local RNA structure and cis-regulatory elements.PMID:35164469 This plasticity may allow the virus to fine-tune protein expression in response to host cellular environments or immune pressure. Moreover, the preferential use of non-canonical sites like A4d and A4h underscores the importance of studying natural infections rather than relying solely on lab-adapted strains.
The discovery of these novel splicing patterns has implications for vaccine design and antiviral therapy. Altered splicing could lead to the production of immunologically distinct protein variants, potentially evading host immune responses. Furthermore, targeting splicing regulation might offer a new avenue for therapeutic intervention. Future research should focus on characterizing the functional properties of these variant proteins, assessing their impact on viral fitness, and evaluating their role in disease progression.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com